Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Factors to consider when selecting JAK inhibitors for patients with MF

Anthony Hunter • 8 Sep 2023
SOHO 2023
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Momelotinib Pacritinib Ruxolitinib

Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses factors to consider when selecting JAK inhibitors to treat patients with myelofibrosis (MF), highlighting pacritinib and momelotinib as suitable agents for the more challenging cytopenic patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Anthony Hunter

3:07
Clinical guidance for the use of JAK inhibitors when treating patients with MF
Anthony Hunter • 8 Sep 2023
1:42
Insights into the LIMBER‐103 trial
Anthony Hunter • 8 Sep 2023

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals